Rachel Humphrey

CIK: 0001579781

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (60.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PYXS

Pyxis Oncology, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

PYXS
Pyxis Oncology, Inc.
Mar 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
45.9K shares-
PYXS
Pyxis Oncology, Inc.
Apr 21, 2025
Sale(S)
Direct
13.9K shares at avg. $1.03$14K
PYXS
Pyxis Oncology, Inc.
Apr 17, 2025
Sale(S)
Direct
200 shares at avg. $0.97$194
PYXS
Pyxis Oncology, Inc.
Apr 14, 2025
Sale(S)
Direct
1.4K shares at avg. $0.97$1K
PYXS
Pyxis Oncology, Inc.
Mar 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
37K shares at avg. $0.98-

		Type	Shares	Price		Ownership
Mar 24, 2026	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	45,867	-	-	Direct
Apr 21, 2025	PYXS Pyxis Oncology, Inc.	Sale(S)	13,896	$1.03	$14,362	Direct
Apr 17, 2025	PYXS Pyxis Oncology, Inc.	Sale(S)	200	$0.97	$194	Direct
Apr 14, 2025	PYXS Pyxis Oncology, Inc.	Sale(S)	1,400	$0.97	$1,362	Direct
Mar 31, 2025	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	36,979	$0.98	-	Direct

1-5 of 5 transactions

About HUMPHREY RACHEL

HUMPHREY RACHEL (SEC CIK 0001579781) files insider reports with the SEC as Director of Pyxis Oncology, Inc. (PYXS).

Signal8 holds 3 ownership filings by HUMPHREY RACHEL, all Form 4s, filed between Apr 2, 2025 and Mar 25, 2026. Those filings report 5 transactions, from Mar 31, 2025 to Mar 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on HUMPHREY RACHEL's filings is in BOSTON, MA.

Recent filings by HUMPHREY RACHEL

Mar 24, 2026: Grant or award of PYXS derivative securities (Form 4, code A).
Apr 21, 2025: Open-market sale of PYXS shares (Form 4, code S).
Apr 17, 2025: Open-market sale of PYXS shares (Form 4, code S).
Apr 14, 2025: Open-market sale of PYXS shares (Form 4, code S).
Mar 31, 2025: Grant or award of PYXS derivative securities (Form 4, code A).

Other insiders filing for Pyxis Oncology, Inc. (PYXS)

GordonMD Global Investments LP, 10% Owner
Civik Thomas, CEO & Chairman of the Board
Dupont Jakob, Director
Wadhane Jitendra, Prin Fin & Acct Officer
FLAVIN JOHN L, Director
Metzger Michael A, Director

How to read Form 4 transaction codes